Compare GH & GNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GH | GNTX |
|---|---|---|
| Founded | 2011 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 5.0B |
| IPO Year | 2018 | 1995 |
| Metric | GH | GNTX |
|---|---|---|
| Price | $94.68 | $21.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 6 |
| Target Price | ★ $121.11 | $28.33 |
| AVG Volume (30 Days) | 1.6M | ★ 1.8M |
| Earning Date | 04-29-2026 | 04-24-2026 |
| Dividend Yield | N/A | ★ 2.20% |
| EPS Growth | ★ 6.74 | N/A |
| EPS | N/A | ★ 1.74 |
| Revenue | $982,021,000.00 | ★ $2,534,268,965.00 |
| Revenue This Year | $33.40 | $6.70 |
| Revenue Next Year | $28.32 | $4.47 |
| P/E Ratio | ★ N/A | $12.55 |
| Revenue Growth | ★ 32.88 | 9.55 |
| 52 Week Low | $36.36 | $20.28 |
| 52 Week High | $120.74 | $29.38 |
| Indicator | GH | GNTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.38 | 46.62 |
| Support Level | $89.32 | $21.69 |
| Resistance Level | $103.16 | $22.21 |
| Average True Range (ATR) | 3.74 | 0.46 |
| MACD | 1.38 | 0.14 |
| Stochastic Oscillator | 91.16 | 77.02 |
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion, with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.